Sponsor or institution

Clinical trials and research at GlaxoSmithKline

• 93Clinical trials
• 57Countries

Newest trials

All recruiting trials (93)

• Influenza vaccine based on mRNA in adults 18-64

  A vaccine made with mRNA is being tested in adults 18 to 64 to see if it triggers a good immune response and is safe.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Glendale, Arizona and 11 other locations · NCT07851246

• Influenza vaccine study for adults 65 and older

  A vaccine trial tests an investigational mRNA flu shot against a licensed flu vaccine in adults 65+ to see if it better prevents flu during the season.

  Recruiting at 163 sites Phase 3 GlaxoSmithKline · Anniston, Alabama and 162 other locations · NCT07805707

• Lifestyle-fit test for risvutatug rezetecan in advanced prostate cancer

  This study tests whether risvutatug rezetecan can help men with metastatic castration-resistant prostate cancer live longer or feel better compared with standard care.

  Recruiting at 6 sites Phase 3 GlaxoSmithKline · Auchenflower, Queensland and 5 other locations · NCT07802704

• Efimosfermin alfa vs placebo for adult alcohol-related liver disease (ALD)

  This trial tests whether efimosfermin alfa is safe and can help people with alcoholic liver disease compared to placebo.

  Recruiting at 13 sites Phase 2 GlaxoSmithKline · Chandler, Arizona and 12 other locations · NCT07791043

• GSK Investigational Medicine GSK3862995B: two formulations in healthy adults

  This early-phase study tests two formulations of GSK3862995B in healthy adults to see how the body handles the drug and whether it is safe and tolerable.

  Recruiting Phase 1 GlaxoSmithKline · Cambridge · NCT07789899

• Combined oral contraceptive timing with Ganfeborole in healthy women

  This study tests how the contraceptive Microgynon behaves in the body when given alone and with Ganfeborole in healthy women who can’t get pregnant.

  Recruiting Phase 1 GlaxoSmithKline · Madrid · NCT07784894

• GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)

  A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · San Diego, California and 6 other locations · NCT07782996

• GSK5784283 as add-on therapy for chronic rhinosinusitis with nasal polyps

  This study tests whether GSK5784283 added to standard care can help adults with chronic rhinosinusitis with nasal polyps feel better and have fewer symptoms.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Los Angeles, California and 7 other locations · NCT07782970

• GSK5784283 as add-on maintenance therapy for nasal polyps in chronic rhinosinusitis

  This study tests whether adding GSK5784283 (Felcorekibart) to standard care helps people with chronic rhinosinusitis with nasal polyps.

  Recruiting at 4 sites Phase 3 GlaxoSmithKline · Sherman Oaks, California and 3 other locations · NCT07782957

• GSK5784283 added to standard COPD therapy vs placebo in moderate to very severe COPD

  This study tests whether adding GSK5784283 to current COPD treatment reduces the rate of COPD flare-ups in adults with eosinophilic COPD and a history of exacerbations.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · Doral, Florida and 6 other locations · NCT07780669

• GSK5784283 added to standard COPD care versus placebo in adults with moderate to very severe COPD

  This study tests whether adding GSK5784283 to a patient’s current COPD treatment helps reduce COPD flare-ups compared with a placebo in adults with eosinophilic COPD and a history of frequent exacerbations.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Cape Coral, Florida and 7 other locations · NCT07780656

• GSK5784283 vs placebo for uncontrolled asthma

  This study tests whether GSK5784283 reduces asthma flare-ups more than a placebo in people with uncontrolled asthma.

  Recruiting Phase 3 GlaxoSmithKline · Miami Lakes, Florida · NCT07780643

• Aletekitug safety study in moderate to severe ulcerative colitis

  This sub-study tests whether aletekitug, an anti-IL-18 medication, is safe and tolerable for people with moderately to severely active ulcerative colitis.

  Recruiting Phase 1 GlaxoSmithKline · Oxford · NCT07747480

• Treatment study to test multiple interventions for moderate to severe ulcerative colitis

  This study tests whether a single master protocol can safely test the anti-IL-18 treatment Aletekitug (GSK1070806) in adults with moderate to severe ulcerative colitis to see if it is tolerable and potentially beneficial.

  Recruiting Phase 1 GlaxoSmithKline · Oxford · NCT07747467

• Efimosfermin vs. placebo in adults with compensated cirrhosis from MASH

  This study tests whether Efimosfermin can help adults with compensated cirrhosis due to MASH compared with placebo.

  Recruiting at 35 sites Phase 3 GlaxoSmithKline · Little Rock, Arkansas and 34 other locations · NCT07704892

• Efimosfermin vs placebo in adults with compensated cirrhosis from MASH

  This study tests whether efimosfermin helps adults with compensated cirrhosis caused by MASH compared with placebo.

  Recruiting at 30 sites Phase 3 GlaxoSmithKline · Little Rock, Arkansas and 29 other locations · NCT07701993

• Depemokimab monotherapy for chronic rhinosinusitis with nasal polyps in Japanese adults

  This study tests depemokimab alone (without intranasal corticosteroids) in adults with chronic rhinosinusitis with nasal polyps in Japan.

  Recruiting at 10 sites Phase 4 GlaxoSmithKline · Ehime and 9 other locations · NCT07701967

• Mo-Rez maintenance therapy in first-line ovarian cancer

  This study tests mocertatug rezetecan (Mo-Rez) alone or with bevacizumab to see if it helps people with newly diagnosed advanced ovarian cancer, compared with bevacizumab alone or no active treatment after initial chemotherapy.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Buenos Aires and 11 other locations · NCT07694427

• Velzatinib for advanced GIST after multiple prior TKIs

  This study tests velzatinib to see if it can shrink or slow tumors in people with metastatic or unresectable GIST who have progressed on or could not tolerate standard therapies.

  Recruiting at 3 sites Phase 2 GlaxoSmithKline · Fukuoka and 2 other locations · NCT07689201

• Mocertatug Rezetecan with Bevacizumab vs Platinum Doublet with Bevacizumab in Platinum-Sensitive Ovarian Cancer

  This trial tests whether mocertatug rezetecan plus bevacizumab helps people with platinum-sensitive ovarian cancer respond better than standard platinum-based therapy plus bevacizumab.

  Recruiting at 9 sites Phase 3 GlaxoSmithKline · Newcastle, New South Wales and 8 other locations · NCT07684612

• Maintenance mocertatug rezetecan with immune therapy for endometrial cancer

  This study tests whether adding Mocertatug Rezetecan to the physician’s chosen immunotherapy helps people with advanced or recurrent endometrial cancer stay on maintenance treatment longer.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Toronto, Ontario and 11 other locations · NCT07684599

• Depemokimab in children aged 6 to 11 with asthma and type-2 inflammation

  This trial tests depemokimab as an add-on treatment for kids 6 to 11 with asthma and type-2 inflammation to see how the drug behaves in the body and whether it is safe and tolerable.

  Recruiting at 3 sites Phase 3 GlaxoSmithKline · Mobile, Alabama and 2 other locations · NCT07671001

• Pan-Salmonella vaccine: safe and immune response in healthy adults

  A single-dose or two-dose vaccine study tests if the GVGH Pan-Salmonella vaccine is safe and produces an immune response in healthy adults in Africa.

  Recruiting Phase 1 GlaxoSmithKline · Bloemfontein · NCT07663032

• BLU-5937 for Refractory Chronic Cough: 24-Week Test in Adults (China Extension)

  This study tests whether BLU-5937 can reduce 24-hour cough frequency in adults with refractory or unexplained chronic cough.

  Recruiting at 38 sites Phase 3 GlaxoSmithKline · Leshan, Sichuan and 37 other locations · NCT07650084

• First-in-human dose-escalation of a monoclonal antibody for malaria safety in healthy adults

  This study tests whether GSK4425689A is safe and tolerable and how it behaves in the body after IV or SC dosing in healthy adults.

  Recruiting Phase 1 GlaxoSmithKline · Manchester · NCT07646353

• Safety comparison of two propellants in an inhaler for adults with asthma

  This study tests whether an inhaler with propellant HFA-152a is as safe as the standard HFA-134a propellant in adults with asthma over 4 weeks.

  Recruiting at 20 sites Phase 3 GlaxoSmithKline · Aventura, Florida and 19 other locations · NCT07645248

• Gepotidacin in Breast Milk of Healthy Lactating Women

  This study will test how gepotidacin behaves in the breast milk of healthy lactating women who are breastfeeding.

  Recruiting Phase 1 GlaxoSmithKline · Las Vegas, Nevada · NCT07645235

• RSV/hMPV vaccine combo and hMPV vaccine in adults and older adults

  This study tests different doses of an investigational RSV/hMPV vaccine, with and without an additional hMPV vaccine, to see if it is safe and triggers a good immune response in younger and older adults.

  Recruiting at 5 sites Phase 1/2 GlaxoSmithKline · Stockbridge, Georgia and 4 other locations · NCT07628049

• GSK5926371 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

  We’re testing whether GSK5926371 is safe and can show activity in adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatment.

  Recruiting at 22 sites Phase 1/2 GlaxoSmithKline · Iowa City, Iowa and 21 other locations · NCT07607925

• Risvutatug rezetecan with ivonescimab in adults with advanced solid tumors

  This study tests a new combination treatment to see if it is safe and potentially effective for adults with advanced solid cancers, including lung cancers.

  Recruiting at 4 sites Phase 1/2 GlaxoSmithKline · Los Angeles, California and 3 other locations · NCT07602855

• Risvutatug Rezetecan in advanced sarcoma: a first-in-cohort study for adolescents and adults

  This study tests Risvutatug Rezetecan (Ris-Rez) to see if it can help people with unresectable, advanced osteosarcoma or soft tissue sarcoma who have already received treatment.

  Recruiting at 13 sites Phase 1/2 GlaxoSmithKline · West Valley City, Utah and 12 other locations · NCT07602777

• GSK4771261 in Healthy Adults Aged 25–55 in Asia and Europe

  This study tests whether GSK4771261 is safe and how it behaves in the body of healthy adults to see if it could be used safely in the future.

  Recruiting Phase 1 GlaxoSmithKline · Groningen · NCT07600450

• Velzatinib vs. Imatinib as frontline treatment for metastatic or unresectable GIST

  This trial tests velzatinib against imatinib as the first systemic therapy for adults with newly diagnosed metastatic or unresectable gastrointestinal stromal tumors to see if velzatinib can delay progression and be tolerable.

  Recruiting at 93 sites Phase 3 GlaxoSmithKline · Scottsdale, Arizona and 92 other locations · NCT07585266

• New antimalarial drug GSK3772701 in adults with uncomplicated falciparum malaria

  A Phase 2A study tests whether the new drug GSK3772701 can be safely given in different doses to adults with uncomplicated falciparum malaria to see if it works.

  Recruiting at 2 sites Phase 2 GlaxoSmithKline · Lambaréné and 1 other locations · NCT07545681

• Camlipixant for IBS-D and IBS-M: a test in adults

  This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.

  Recruiting at 114 sites Phase 2 GlaxoSmithKline · Anniston, Alabama and 113 other locations · NCT07519395

• Recombinant zoster (Shingrix) to see if it lowers new dementia diagnoses in people 76 and older in Finland.

  This trial will test whether the Shingrix shingles vaccine lowers the chance of a new dementia diagnosis in people aged 76 or older who live in Finland.

  Recruiting at 8 sites Phase 4 GlaxoSmithKline · Espoo and 7 other locations · NCT07502560

• mRNA combination vaccine for seasonal flu and COVID-19 in adults 65–85

  This trial will test a new mRNA vaccine that combines protection against seasonal flu and COVID-19 in healthy adults aged 65 to 85.

  Recruiting at 12 sites Phase 1 GlaxoSmithKline · Anniston, Alabama and 11 other locations · NCT07464314

• Depemokimab added to standard care in adults and adolescents with Type 2 asthma at risk of flare-ups

  This study tests whether adding depemokimab to usual asthma care can reduce worsening episodes in people with Type 2 asthma who have had recent flare-ups.

  Recruiting at 17 sites Phase 3 GlaxoSmithKline · Little Rock, Arkansas and 16 other locations · NCT07456033

• GSK5533524 alone or with other treatments for adults with advanced solid tumors

  This trial tests whether the new drug GSK5533524, given alone or with other therapies, is safe, tolerable, and can shrink or slow advanced solid tumors in adults who have no standard treatment options left.

  Recruiting at 20 sites Phase 1 GlaxoSmithKline · Philadelphia, Pennsylvania and 19 other locations · NCT07438782

• Measles, Mumps, Rubella and Varicella vaccine booster in healthy children aged 15 months to 6 years

  This study tests whether the investigational MMRVNS vaccine given as a second dose is safe and can provoke an immune response in healthy children who previously received a first MMRV-containing vaccine dose.

  Recruiting at 17 sites Phase 3 GlaxoSmithKline · Birmingham, Alabama and 16 other locations · NCT07406360

• GSK5926371 for B-cell driven autoimmune rheumatic diseases

  This trial will test whether the experimental drug GSK5926371 is safe and well tolerated in adults with B-cell-driven autoimmune rheumatic diseases such as lupus and rheumatoid arthritis.

  Recruiting at 19 sites Phase 1 GlaxoSmithKline · Buenos Aires and 18 other locations · NCT07371468

• Efimosfermin alfa for adults with liver impairment

  This trial will test a single dose of efimosfermin alfa in adults with cirrhosis-related hepatic impairment from steatotic liver disease, with and without significant alcohol use, to measure drug levels and safety.

  Recruiting at 5 sites Phase 1 GlaxoSmithKline · Rialto, California and 4 other locations · NCT07358546

• Testing GSK5471713 in adults with metastatic castration-resistant prostate cancer

  This trial will test whether the experimental drug GSK5471713 is safe, tolerable, and shows early signs of benefit in adults with metastatic castration-resistant prostate cancer who have progressed on androgen-deprivation therapy and prior AR pathway inhibitors.

  Recruiting at 20 sites Phase 1/2 GlaxoSmithKline · La Jolla, California and 19 other locations · NCT07332455

• Long-term immune response to altSonflex1-2-3 vaccine in African children

  This study checks whether the immune response from the altSonflex1-2-3 Shigella vaccine persists 1 to 3 years after vaccination in African children who previously received the vaccine.

  Recruiting Phase 2 GlaxoSmithKline · Kericho · NCT07320716

• GVGH iNTS-TCV vaccine to prevent invasive nontyphoidal Salmonella disease and typhoid in infants

  This study will see if the GVGH iNTS-TCV vaccine given at 6 weeks or 6 months is safe and triggers an immune response in infants.

  Recruiting Phase 2 GlaxoSmithKline · Banjul · NCT07286370

• Mo-Rez vs chemotherapy for endometrial cancer after platinum-based therapy

  In people with endometrial cancer who have already had platinum therapy, this study tests mocertatug rezetecan (Mo-Rez) against standard chemotherapy to see how well it works and how safe it is.

  Recruiting at 56 sites Phase 3 GlaxoSmithKline · Birmingham, Alabama and 55 other locations · NCT07286331

• Mocertatug Rezetecan vs Standard Care for Platinum-Resistant Ovarian Cancer

  This study tests mocertatug rezetecan (Mo-Rez) against standard treatments to see if it helps people with platinum-resistant ovarian cancer behave better and handle side effects.

  Recruiting at 22 sites Phase 3 GlaxoSmithKline · Randwick, New South Wales and 21 other locations · NCT07286266

• GSK5764227 given with standard therapies for advanced solid tumors

  This trial will test whether GSK5764227, a drug that delivers a toxin directly to cancer cells, can be safely given alongside standard treatments in adults with advanced solid tumors such as metastatic colorectal cancer or metastatic castration-resistant prostate cancer.

  Recruiting at 22 sites Phase 1 GlaxoSmithKline · Reunion, Florida and 21 other locations · NCT07277270

• Belantamab mafodotin with standard myeloma medicines for relapsed or refractory multiple myeloma

  This study tests whether giving belantamab mafodotin less often together with standard myeloma medicines helps adults whose multiple myeloma has come back or stopped responding.

  Recruiting at 59 sites Phase 2 GlaxoSmithKline · Los Alamitos, California and 58 other locations · NCT07227311

• Belantamab Mafodotin with a chemotherapy combo for newly diagnosed AL amyloidosis

  This study tests whether adding belantamab mafodotin to a regimen of cyclophosphamide, bortezomib, and dexamethasone can help adults with newly diagnosed AL amyloidosis.

  Recruiting at 16 sites Phase 2 GlaxoSmithKline · Los Angeles, California and 15 other locations · NCT07224672

• Efimosfermin alfa for adults with biopsy-confirmed F2 or F3 MASH

  This trial will test whether efimosfermin alfa can resolve steatohepatitis and improve liver-related outcomes in adults with biopsy-confirmed F2 or F3 MASH.

  Recruiting at 91 sites Phase 3 GlaxoSmithKline · Chandler, Arizona and 90 other locations · NCT07221227

• Efimosfermin alfa injections for adults with F2–F3 MASH

  This study tests whether efimosfermin alfa injections are safe and tolerable for adults (18–75) with known or suspected metabolic dysfunction-associated steatohepatitis (MASH) and F2–F3 fibrosis.

  Recruiting at 66 sites Phase 3 GlaxoSmithKline · Arcadia, California and 65 other locations · NCT07221188

• IDRX-42 versus sunitinib for adults with advanced gastrointestinal stromal tumors after imatinib

  This test compares IDRX-42 (GSK6042981) with sunitinib in adults with advanced or unresectable GIST who have already been treated with imatinib to see which controls the cancer better and is safer.

  Recruiting at 156 sites Phase 3 GlaxoSmithKline · Phoenix, Arizona and 155 other locations · NCT07218926

• GSK5460025 alone or with other anti-cancer drugs for advanced solid tumors

  This trial will test whether the experimental drug GSK5460025, alone or combined with other cancer medicines, can shrink tumors and be safe for people with advanced colorectal or other solid tumors that are dMMR/MSI-H or have unknown MMR/MSI status.

  Recruiting at 27 sites Phase 1/2 GlaxoSmithKline · Aurora, Colorado and 26 other locations · NCT07213609

• GSK's new drug for adults with bronchiectasis

  A new drug (GSK3862995B) is being tested in adults with bronchiectasis to see if it works better than placebo and to check safety and how the body handles it.

  Recruiting at 134 sites Phase 2 GlaxoSmithKline · Mobile, Alabama and 133 other locations · NCT07201051

• Early depemokimab treatment for COPD with type 2 (eosinophilic) inflammation

  This trial will test whether adding depemokimab early to standard care helps adults with moderate-to-severe COPD who have type 2 (eosinophilic) inflammation.

  Recruiting at 121 sites Phase 3 GlaxoSmithKline · Newport Beach, California and 120 other locations · NCT07177339

• Dostarlimab with carboplatin–paclitaxel for advanced or recurrent endometrial cancer in Chinese patients with dMMR/MSI-H

  This Phase 2 trial will test whether adding dostarlimab to carboplatin and paclitaxel helps Chinese patients with advanced or recurrent dMMR/MSI‑H endometrial cancer respond to treatment and tolerate the combination.

  Recruiting Phase 2 GlaxoSmithKline · Jinan, Shandong · NCT07108270

• Open-label extension of GSK4527226 for people with early Alzheimer's disease

  This extension gives GSK4527226 to people with early Alzheimer's disease who completed the parent study to see if the medicine stays safe and helps over the long term.

  Recruiting at 33 sites Phase 2 GlaxoSmithKline · Maitland, Florida and 32 other locations · NCT07105709

• Risvutatug rezetecan vs topotecan for relapsed extensive-stage small cell lung cancer

  This trial tests whether Ris-Rez helps adults with relapsed extensive-stage small cell lung cancer shrink tumors and live longer compared with standard topotecan.

  Recruiting at 144 sites Phase 3 GlaxoSmithKline · Los Angeles, California and 147 other locations · NCT07099898

• Safety and immune response testing of a 4-component Strep A vaccine with Alum or AS37 in healthy 18–25-year-olds

  This will test three dose levels of two new Strep A vaccine formulations (one with Alum, one with AS37) in healthy 18–25-year-olds to see if they are safe and trigger immune responses.

  Recruiting at 2 sites Phase 1 GlaxoSmithKline · Botany, New South Wales and 1 other locations · NCT07085702

• Lower-dose and alternate-schedule RTS,S malaria vaccine for young children

  This project will test if smaller doses and different schedules of the RTS,S malaria vaccine are safe and help build immunity in healthy children aged 5 to 60 months who live where malaria is common.

  Recruiting at 2 sites Phase 2 GlaxoSmithKline · Kigali and 1 other locations · NCT07036159

• GSK5458514 alone or with other anti-cancer drugs for prostate cancer

  This trial will test the safety and how the body handles GSK5458514 alone or combined with other cancer medicines in adult men with metastatic castration-resistant prostate cancer.

  Recruiting at 20 sites Phase 1/2 GlaxoSmithKline · Phoenix, Arizona and 19 other locations · NCT06990880

• Depemokimab imaging and bronchoscopy for eosinophilic asthma

  This trial tests whether depemokimab changes lung structure and function in people with eosinophilic (Type 2) asthma using HRCT and bronchoscopy.

  Recruiting at 49 sites Phase 3 GlaxoSmithKline · Brooksville, Florida and 49 other locations · NCT06979323

• Depemokimab for adults with COPD and eosinophilic (type 2) inflammation

  This study will test whether adding depemokimab to usual inhaled therapy can reduce flare-ups and improve outcomes for adults (40–80) with moderate-to-severe COPD and high blood eosinophils.

  Recruiting at 193 sites Phase 3 GlaxoSmithKline · Sheffield, Alabama and 192 other locations · NCT06961214

• Depemokimab — a long‑acting biologic for adults with COPD and type 2 inflammation.

  This trial will test whether adding depemokimab, a long‑acting injectable biologic, reduces flare-ups and improves symptoms in adults with uncontrolled moderate-to-severe COPD who have type 2 inflammation.

  Recruiting at 281 sites Phase 3 GlaxoSmithKline · Bakersfield, California and 280 other locations · NCT06959095

• Evaluating efimosfermin for patients with compensated cirrhosis and metabolic dysfunction

  This study is testing if a new treatment called efimosfermin can help people with compensated cirrhosis and metabolic dysfunction feel better and improve their liver health.

  Recruiting at 30 sites Phase 2 GlaxoSmithKline · Chandler, Arizona and 29 other locations · NCT06920043

• GSK5764227 for adults with advanced unresectable gastrointestinal cancers

  This test tries the drug GSK5764227, alone or with other treatments, in adults with advanced gastrointestinal cancers that cannot be removed by surgery and who have had prior therapy.

  Recruiting at 85 sites Phase 1/2 GlaxoSmithKline · Los Alamitos, California and 84 other locations · NCT06885034

• Immune response and safety of an investigational chickenpox vaccine and MMR given by muscle injection to healthy 12–15 month-olds

  This trial will test whether GSK's investigational chickenpox vaccine given with MMR as a muscle shot is safe and produces a good immune response in healthy children aged 12 to 15 months, compared with Merck's chickenpox vaccine given under the skin.

  Recruiting at 21 sites Phase 3 GlaxoSmithKline · Tucson, Arizona and 21 other locations · NCT06855160

• Momelotinib for adults with low‑risk myelodysplastic syndrome

  This trial will test if momelotinib can reduce red blood cell transfusion needs and is safe in adults with low‑risk myelodysplastic syndrome who are refractory or intolerant to prior ESA or luspatercept.

  Recruiting at 39 sites Phase 2 GlaxoSmithKline · Goodyear, Arizona and 38 other locations · NCT06847867

• Second-dose chickenpox vaccine given three months after the first dose for 12–15 month olds

  This test checks whether GSK’s investigational chickenpox vaccine is safe and produces a strong immune response as the second dose when given to healthy children three months after their first dose at age 12–15 months.

  Recruiting at 6 sites Phase 3 GlaxoSmithKline · Salvaleón de Higüey, La Altagracia Province and 5 other locations · NCT06806137

• Combining GSK5733584 with cancer therapies for advanced tumors

  This study is testing a new cancer drug called GSK5733584 to see if it works better when combined with other treatments for people with advanced tumors who haven't responded to standard therapies.

  Recruiting at 80 sites Phase 1/2 GlaxoSmithKline · La Jolla, California and 82 other locations · NCT06796907

• Investigating a new chickenpox vaccine for healthy children aged 12 to 15 months

  This study is testing a new chickenpox vaccine in healthy kids aged 12 to 15 months to see if it works well and is safe compared to an existing vaccine.

  Recruiting at 87 sites Phase 3 GlaxoSmithKline · Mobile, Alabama and 96 other locations · NCT06740630

• Investigating the long-term effects of Belimumab in adults with lung disease related to systemic sclerosis

  This study is testing if the medication Belimumab can help adults with lung disease related to systemic sclerosis feel better and slow down their disease over the long term.

  Recruiting at 41 sites Phase 3 GlaxoSmithKline · Los Angeles, California and 40 other locations · NCT06716606

• Vaccine for preventing urinary tract infections in adults

  This study is testing a new vaccine to see if it can help prevent urinary tract infections in adults, especially women who often get them.

  Recruiting at 8 sites Phase 1/2 GlaxoSmithKline · Lenexa, Kansas and 7 other locations · NCT06702449

• Safety assessment of a new chickenpox vaccine for young children

  This study tests a new chickenpox vaccine in healthy kids aged 12 to 15 months to see if it's safe compared to the already approved vaccine.

  Recruiting at 37 sites Phase 3 GlaxoSmithKline · Phoenix, Arizona and 45 other locations · NCT06693895

• Comparing two treatment combinations for newly diagnosed multiple myeloma patients who can't undergo stem cell transplantation

  This study is testing if a new combination of medications can help people with newly diagnosed multiple myeloma who can't have a stem cell transplant live longer without their disease getting worse compared to a different treatment combination.

  Recruiting at 181 sites Phase 3 GlaxoSmithKline · Mobile, Alabama and 180 other locations · NCT06679101

• Comparing Tafenoquine and Primaquine for treating P. Vivax Malaria in India

  This study is testing whether Tafenoquine combined with Chloroquine works better and is safer than Primaquine with Chloroquine for treating P. Vivax malaria in people aged 2 and older in India.

  Recruiting at 5 sites Phase 3 GlaxoSmithKline · Ahmedabad and 4 other locations · NCT06666491

• GSK4532990 for adults with alcohol-related liver disease

  This trial will test whether GSK4532990 is safe and helps adults aged 18 to 70 who have alcohol-related liver disease compared with placebo.

  Recruiting at 138 sites Phase 2 GlaxoSmithKline · Chandler, Arizona and 139 other locations · NCT06613698

• Testing GSK4527363 in healthy individuals and those with systemic lupus erythematosus

  This study is testing a new drug called GSK4527363 in healthy people and those with systemic lupus erythematosus to see how safe it is and how it works in the body.

  Recruiting at 25 sites Phase 1 GlaxoSmithKline · Scottsdale, Arizona and 27 other locations · NCT06576271

• Evaluating Belimumab for Lung Disease Linked to Autoimmune Conditions

  This study is testing if the medication belimumab can help adults with lung disease caused by autoimmune conditions feel better and breathe easier.

  Recruiting at 126 sites Phase 3 GlaxoSmithKline · Los Angeles, California and 131 other locations · NCT06572384

• Testing a new treatment for colon cancer using dostarlimab and chemotherapy

  This study is testing if combining a new drug called dostarlimab with chemotherapy can help people with certain types of colon cancer do better before surgery.

  Recruiting at 32 sites Phase 2 GlaxoSmithKline · Aalst and 32 other locations · NCT06567782

• Testing GSK5764227 in patients with advanced solid tumors

  This study is testing a new cancer drug called GSK5764227 to see if it is safe and effective for people with advanced solid tumors, both on its own and with other treatments.

  Recruiting at 66 sites Phase 1 GlaxoSmithKline · Stanford, California and 66 other locations · NCT06551142

• Assessing the effectiveness of belimumab for lupus nephritis treatment

  This study is testing how well belimumab works for adults with active lupus nephritis to see if it helps protect their kidney function over time.

  Recruiting at 7 sites GlaxoSmithKline · Baltimore, Maryland and 6 other locations · NCT06527872

• Combining Momelotinib and Luspatercept for Myelofibrosis Treatment

  This study is testing if combining two medications, momelotinib and luspatercept, can help people with myelofibrosis who need blood transfusions feel better and reduce their transfusion needs.

  Recruiting at 33 sites Phase 2 GlaxoSmithKline · Ann Arbor, Michigan and 32 other locations · NCT06517875

• Comparing two types of inhalers for mild asthma treatment

  This study is testing two different types of inhalers to see which one helps people with mild asthma breathe better.

  Recruiting Phase 1 GlaxoSmithKline · Manchester, Greater Manchester · NCT06433921

• Evaluating GSK5733584 for advanced solid tumors

  This study is testing a new injectable treatment called GSK5733584 to see if it's safe and how it works for people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 64 sites Phase 1 GlaxoSmithKline · Birmingham, Alabama and 64 other locations · NCT06431594

• Comparing Dostarlimab to Placebo after Chemoradiation for Head and Neck Cancer

  This study is testing if the immunotherapy drug Dostarlimab can help adults with advanced head and neck cancer feel better after they finish their chemoradiation treatment, compared to a placebo.

  Recruiting at 256 sites Phase 3 GlaxoSmithKline · Jonesboro, Arkansas and 276 other locations · NCT06256588

• Evaluating the safety of ibrexafungerp in pregnant women and their infants

  This study is testing whether ibrexafungerp is safe for pregnant women and their babies by looking at their health during and after pregnancy.

  Recruiting GlaxoSmithKline · New Delhi, Vasant Vihar · NCT05908682

• Evaluating belimumab for treating lung disease in systemic sclerosis

  This study is testing if belimumab can help improve lung function and overall quality of life for adults with lung disease caused by systemic sclerosis.

  Recruiting at 114 sites Phase 2/3 GlaxoSmithKline · Phoenix, Arizona and 133 other locations · NCT05878717

• Evaluating dostarlimab for resectable colon cancer

  This study is testing if adding a new immunotherapy called dostarlimab to standard chemotherapy can help people with certain types of resectable colon cancer do better.

  Recruiting at 229 sites Phase 3 GlaxoSmithKline · Tucson, Arizona and 265 other locations · NCT05855200

• Investigating Belantamab for treating Multiple Myeloma

  This study is testing a new treatment called belantamab, both by itself and with another drug, to see if it can help people with hard-to-treat multiple myeloma feel better.

  Recruiting at 39 sites Phase 1/2 GlaxoSmithKline · Bullhead City, Arizona and 43 other locations · NCT05714839

• Long-term niraparib treatment for people who completed a prior GSK/TESARO niraparib protocol

  This extension lets people with ovarian or breast cancer who finished a GSK/TESARO niraparib protocol keep taking niraparib to see if it remains safe over the long term.

  Recruiting at 18 sites Phase 2 GlaxoSmithKline · Tucson, Arizona and 24 other locations · NCT04641247

• Testing a vaccine to prevent shingles in children with kidney transplants

  This study is testing a new vaccine to see if it can safely prevent shingles in children aged 1-17 who have had a kidney transplant.

  Recruiting at 26 sites Phase 1/2 GlaxoSmithKline · Brussels and 30 other locations · NCT04006808

Quick answers

How many clinical trials run by GlaxoSmithKline are recruiting right now?

93, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 57 countries. The most sites are in United States (64 trials), Japan (43 trials), United Kingdom (37 trials), Canada (35 trials), Spain (34 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 40, Phase 2: 18, Phase 1: 18, Phase 1/2: 12. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →